Caitlin Pickart
Psychiatry · Costa Mesa, CANPI 1275657157
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 298 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Johnson & Johnson at 27.7% of the total. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $22.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$776
- Indivior Inc.$744
- Neurocrine Biosciences, Inc.$644
- Teva Pharmaceuticals USA, Inc.$544
- plus $750 from 5 others
What the payments were for
- Food & beverage$6,630100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 90 | $1,841 |
| Alkermes, Inc. | 56 | $1,337 |
| Otsuka America Pharmaceutical, Inc. | 37 | $776 |
| Indivior Inc. | 29 | $744 |
| Neurocrine Biosciences, Inc. | 25 | $644 |
| Teva Pharmaceuticals USA, Inc. | 30 | $544 |
| Vanda Pharmaceuticals Inc. | 12 | $320 |
| E.r. Squibb & Sons, L.L.C. | 7 | $204 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $128 |
| Sunovion Pharmaceuticals Inc. | 4 | $71 |
| Luye Pharma (USA) Ltd. | 2 | $28 |
How this compares
$6,636 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AristadaAripiprazole Lauroxil | 12 | $35,567 |
| Clozapine | 24 | $3,163 |
| Fluphenazine Decanoate | 11 | $937 |
| Quetiapine Fumarate | 18 | $670 |
| Benztropine Mesylate | 29 | $480 |
| Aripiprazole | 21 | $431 |
| Bupropion XlBupropion Hcl | 18 | $252 |
| Risperidone | 24 | $233 |
| Trazodone Hcl | 19 | $227 |
| Lorazepam | 16 | $158 |
| Divalproex Sodium | 11 | $139 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Alkermes, Inc.Aristada | $1,337 | $35,56712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Costa Mesa
- Alejandro AlvaCosta Mesa$271K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.